Cas:107932-97-8 2-(1H-imidazo[4,5-b]pyridin-2-yl)acetonitrile manufacturer & supplier

Chemical Name:2-(1H-imidazo[4,5-b]pyridin-2-yl)acetonitrile

CAS.NO:107932-97-8

Synonyms:2-Cyanomethyl-impy

Molecular Formula:C₈H₆N₄

Molecular Weight:158.16000

HS Code:2933990090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:468.1ºC at 760mmHg

Density:1.381g/cm3

Index of Refraction:1.698

PSA:65.36000

Exact Mass:158.05900

LogP:1.02398

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like 2-Cyanomethyl-impy chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,2-Cyanomethyl-impy physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,2-Cyanomethyl-impy Use and application,2-Cyanomethyl-impy technical grade,usp/ep/jp grade.

Related News: Ten domestic API leading enterprises of CSPC, Puluo Pharmaceutical, Huahai Pharmaceutical, Chuang Nuo Pharmaceutical, Federal Pharmaceuticals, Zhejiang Pharmaceutical, Yifan Pharmaceutical, Jiangxi Tianxin, Zhejiang Chemical Industry, and Xinhua Pharmaceutical rank among China’s API exporters The top ten in the list. 2-(1H-imidazo[4,5-b]pyridin-2-yl)acetonitrile manufacturer As far as chemical raw materials are concerned, China occupies a large share in the field of bulk raw materials and has become one of the world’s largest suppliers of chemical raw materials. 2-(1H-imidazo[4,5-b]pyridin-2-yl)acetonitrile supplier This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.? 2-(1H-imidazo[4,5-b]pyridin-2-yl)acetonitrile vendor For one, people who are surrounded by others of similar body size may not perceive their weight to be outside of the norm and therefore not seek out bariatric surgery,” said Sandon. “[And] there are differences in ethnicities and culture between states with the highest rates of obesity compared to states with lower rates. 2-(1H-imidazo[4,5-b]pyridin-2-yl)acetonitrile factory This dosage form may also support combination therapy modalities.? To date, over 400 patients have been dosed with the oral formulation of rigosertib in clinical trials.? Combination therapy of oral rigosertib with azacitidine, the standard of care in HR-MDS, has also been studied. Currently, oral rigosertib is being developed as a combination therapy together with azacitidine for patients with higher-risk MDS who require HMA therapy.?